---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-005946"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-04-24T23:59:59+00:00"
generated_at: "2026-05-23T07:24:34.073971+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "medium"
source: SEC EDGAR
---

# Kairos Pharma CEO letter updates ENV105 trials, DoD grant, and analyst coverage

## Summary
- ENV105 in Phase 2 prostate cancer and Phase 1 lung cancer trials; interim efficacy data expected end of Q2 2025.
- CSO lab received $876k DoD grant for biomarker study; trial sites expanded to University of Utah and City of Hope.
- Developing KROS101 GITR ligand agonist; data presented at AACR, SITC, and upcoming ASCO.
- Non-dilutive government grants received; robust IP portfolio; analyst coverage from EF Hutton, Maxim, HC Wainwright, and others.
- Financially strong due to recent private placement and non-dilutive funding; attending D. Boral and HC Wainwright conferences.

## SEC filing metadata
- accession: 0001641172-25-005946
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-04-24T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/0001641172-25-005946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000164117225005946/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-005946
- JSON: https://secwatch.observer/filing/0001641172-25-005946.json
- Plain text: https://secwatch.observer/filing/0001641172-25-005946.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.